Importantly, attempting to eradicate this resistant cancer cell population by the administration of lovastatin alone does not significantly affect cell viability in CD133 + cells, however co-administration of lovastatin and paclitaxel induces cell death in CD133 + cells by disrupting lipid raft integrity which consequently abrogates ABC transporter activity (Gupta et al., 2018). Here, PROM1 is linked to cancer.